Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSD | P07339 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22978326 | 0.74 | CTSD (0.31) | CTSD | |
| SCHEMBL301716 | 0.74 | CTSD (0.31) | CTSD | |
| SCHEMBL2230540 | 0.69 | CTSD (0.43) | CTSD | |
| SCHEMBL3122693 | 0.69 | CTSD (0.32) | CTSD | |
| SCHEMBL6300398 | 0.65 | CTSD (0.32) | CTSD | |
| Hydrochloric Acid SCHEMBL9078259 | 0.65 | CTSD (0.32) | CTSD | |
| Bromide SCHEMBL9220366 | 0.65 | CTSD (0.32) | CTSD | |
| SCHEMBL22978329 | 0.63 | — | — | |
| SCHEMBL5616521 | 0.63 | CTSD (0.35) | CTSD | |
| SCHEMBL4652458 | 0.63 | CTSD (0.35) | CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025123046-A1 | SYNTHESIS OF LEUCINE-RICH REPEAT KINASE 2 MODULATORS | ARVINAS OPERATIONS, INC. (US) | 2025-06-12 | — | — | WO | claimed |
| WO-2025123046-A1 | SYNTHESIS OF LEUCINE-RICH REPEAT KINASE 2 MODULATORS | ARVINAS OPERATIONS, INC. (US) | 2025-06-12 | — | — | WO | disclosed |
| US-11407703-B2 | Method for converting hydroxyl group of alcohol | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2022-08-09 | — | — | US | disclosed |
| US-20210047254-A1 | METHOD FOR CONVERTING HYDROXYL GROUP OF ALCOHOL | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2021-02-18 | — | — | US | disclosed |
| EP-2989099-A1 | A PROCESS FOR THE SYNTHESIS OF MARAVIROC | Zentiva K.S. (CZ) | 2016-03-02 | — | — | EP | disclosed |
| WO-2014173375-A1 | A PROCESS FOR THE SYNTHESIS OF MARAVIROC | ZENTIVA, K.S. (CZ) | 2014-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11407703-B2 | Method for converting hydroxyl group of alcohol | ADH1C, CBR1, NAP1L4 | CTSD 3971/4885 |
| US-20210047254-A1 | METHOD FOR CONVERTING HYDROXYL GROUP OF ALCOHOL | ADH1C, CBR1, NAP1L4 | CTSD 3971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.